<DOC>
	<DOCNO>NCT00006114</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy combination mitoxantrone vinorelbine term response rate , progression free survival , overall survival , quality life patient metastatic hormone refractory adenocarcinoma prostate . - Determine toxicity treatment regimen patient . OUTLINE : This multicenter study . Patients receive vinorelbine IV day 1 8 mitoxantrone IV day 8 . Treatment repeat every 3 week 9 course absence disease progression unacceptable toxicity . Quality life assess prior treatment , prior course , 2 month study completion . Patients follow every 3 month disease progression . PROJECTED ACCRUAL : A total 14-39 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IV hormone refractory adenocarcinoma prostate Progressive disease despite hormonal therapy orchiectomy No brain metastasis PATIENT CHARACTERISTICS : Age : 18 80 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 2,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 9 g/dL Hepatic : Alkaline phosphatase great 2 time upper limit normal ( ULN ) ( unless bone metastasis ) Bilirubin le 2 time ULN Renal : Creatinine le 2 time ULN Cardiovascular : Adequate cardiac function Other : No prior malignancy except curatively treat basal squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : See Disease Characteristics Prior corticosteroid allow start least 8 week prior study Radiotherapy : At least 8 week since prior extensive radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>